Literature DB >> 25390860

Continuation of anticoagulant and antiplatelet therapy during phacoemulsification cataract surgery.

Andrzej Grzybowski1, Francisco J Ascaso, Konrad Kupidura-Majewski, Mark Packer.   

Abstract

PURPOSE OF REVIEW: The objective of this review is to evaluate the result of cataract surgery in patients continuing antiplatelet and/or anticoagulant treatment. RECENT
FINDINGS: The number of elderly patients using anticoagulant and antiplatelet treatment in prevention of venous thromboembolism has significantly increased in recent years. It was believed for many years that those patients might be at higher risk for complications during ocular surgery. Thus, different strategies were proposed to prevent these complications, including discontinuation of anticoagulants, dose reduction, or low-molecular-weight heparin replacement. We performed a PubMed search over a period of 7 years (2007-2013) about possible intraoperative and postoperative complications in patients receiving anticoagulant and/or antiplatelet therapy at the time of cataract surgery. No significant increase in intraoperative or postoperative complications has been identified.
SUMMARY: Phacoemulsification of uncomplicated cataracts with intraocular lens implantation can be performed safely in high-risk patients, taking both anticoagulants and antiplatelet drugs when topical anesthesia is administered and cataract surgery is performed through a clear corneal incision by a skilled surgeon.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25390860     DOI: 10.1097/ICU.0000000000000117

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  9 in total

1. 

Authors:  Berrin Günaydın; Ömer Kurtipek
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-06-01

2.  Risk of intraocular hemorrhage with oral anticoagulants in ocular surgery.

Authors:  A Grzybowski; K Kupidura-Majewski
Journal:  Eye (Lond)       Date:  2017-09-01       Impact factor: 3.775

3.  Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).

Authors:  Irina S Barequet; Tzukit Zehavi-Dorin; Nirit Bourla; Ilia Tamarin; Joseph Moisseiev; Ophira Salomon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-10-22       Impact factor: 3.117

4.  Identification and Description of Reliable Evidence for 2016 American Academy of Ophthalmology Preferred Practice Pattern Guidelines for Cataract in the Adult Eye.

Authors:  Asieh Golozar; Yujiang Chen; Kristina Lindsley; Benjamin Rouse; David C Musch; Flora Lum; Barbara S Hawkins; Tianjing Li
Journal:  JAMA Ophthalmol       Date:  2018-05-01       Impact factor: 7.389

5.  AMBULATORY EYE SURGERY AND ANTITHROMBOTIC THERAPY - NEW APPROACHES.

Authors:  Tatjana Šimurina; Marija Danilović Luketić; Sandra Graf Župčić; Boris Mraović
Journal:  Acta Clin Croat       Date:  2021-12       Impact factor: 0.932

6.  [Anticoagulation and platelet aggregation inhibition : What needs to be considered in the ophthalmological practice].

Authors:  Oliver Zeitz; Laura Wernecke; Nicolas Feltgen; Christoph Sucker; Jürgen Koscielny; Thomas Dörner
Journal:  Ophthalmologe       Date:  2021-07-19       Impact factor: 1.059

7.  Pupil-occluding organized hyphema anterior to the intraocular lens treated by neodymium: yttrium-aluminum-garnet laser: a case report.

Authors:  Moosang Kim; Seung-Jun Lee; Sang Beom Han; Hee Kyung Yang; Joon Young Hyon
Journal:  Int Med Case Rep J       Date:  2016-07-07

Review 8.  Risk of Hemorrhage during Needle-Based Ophthalmic Regional Anesthesia in Patients Taking Antithrombotics: A Systematic Review.

Authors:  Augusto Takaschima; Patricia Marchioro; Thiago M Sakae; André L Porporatti; Luis André Mezzomo; Graziela De Luca Canto
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

9.  Continuation of Aspirin Therapy before Cataract Surgery with Different Incisions: Safe or Not?

Authors:  Qingjian Li; Yiwen Qian; Yu Zhang; Gaoyuan Sun; Xian Zhou; Zhiliang Wang
Journal:  J Ophthalmol       Date:  2018-05-13       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.